
Sign up to save your podcasts
Or
Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content:
4.6
162162 ratings
Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content:
766 Listeners
38,750 Listeners
140 Listeners
325 Listeners
21,636 Listeners
882 Listeners
502 Listeners
43,841 Listeners
6,630 Listeners
703 Listeners
3,333 Listeners
17 Listeners
19 Listeners
12 Listeners
20 Listeners
6 Listeners
90 Listeners
29 Listeners
192 Listeners
371 Listeners
6,293 Listeners
18 Listeners